Biochemical and Objective Response to Abiraterone Acetate Withdrawal: Incidence and Clinical Relevance of a New Scenario for Castration-resistant Prostate Cancer - 26/10/13
, Antonio Palermo b, Antonello Veccia a, Francesca Maines a, Franca Chierichetti b, Alfredo Berruti c, Enzo Galligioni aAbstract |
Objective |
To describe the incidence and clinical relevance of biochemical and objective responses to abiraterone acetate (AA) withdrawal (AAWD) in patients with castration-resistant prostate cancer (CRPC).
Materials and Methods |
Twenty-six patients with progressive CRPC treated with first-line docetaxel-based chemotherapy were administered with AA at the standard dose of 1000 mg/day in combination with prednisone until progression. The patients were regularly followed up during treatment and after AAWD.
Results |
Nineteen of the 26 patients discontinued AA because of progression. Three of the patients undergoing AAWD experienced a biochemical response, which was accompanied by a metabolic and radiological response as revealed by choline positron emission tomography in 2 cases.
Conclusion |
Regardless of the underlying molecular bases, AAWD response does not occur rarely. It is sometimes long-lasting and accompanied by a metabolic and radiographic improvement. AAWD response should be taken into account when further therapeutic strategies are planned in patients with CRPC with progressive disease during abiraterone therapy.
Le texte complet de cet article est disponible en PDF.Plan
| Financial Disclosure: The authors declare that they have no relevant financial interests. |
Vol 82 - N° 5
P. 1090-1093 - novembre 2013 Retour au numéro
Article précédent
- Activation of Mammalian Target of Rapamycin Signaling Pathway Markers in Minute Adenocarcinoma of the Prostate
- Sheila F. Faraj, Roula Albadine, Alcides Chaux, Nilda Gonzalez-Roibon, Jessica Hicks, Elizabeth Humphreys, Alan Partin, George J. Netto
- Impacts of Histological Prostatitis on Sexual Function and Lower Urinary Tract Symptoms in Patients With Benign Prostatic Hyperplasia
- Guang-chun Wang, Jun-hua Zheng, Bin Yang, Jian-ping Che, Yang Yan, Jiang Geng, Min Liu, Jian-hua Huang, Sheng-qiang Xia, Bo Peng
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?